Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-RESERP vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
50-100 hours (terminal); prolonged in renal impairment, leading to accumulation on repeated dosing.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Hydrochlorothiazide is not extensively metabolized; it is excreted unchanged in urine. Reserpine is extensively metabolized in the liver by hydrolysis and conjugation.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal: 30-40% as unchanged reserpine; biliary/fecal: 60-70% as metabolites.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
96% bound to albumin and alpha1-acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
1.5-2.5 L/kg; extensive tissue distribution with high affinity for adrenergic neurons.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 50-60% (first-pass metabolism); IM: ~100%.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated if e GFR <30 m L/min/1.73m² due to HCTZ ineffectiveness. For GFR 30-50 m L/min: reduce HCTZ to 12.5-25 mg daily; reserpine unchanged. Monitor serum creatinine and electrolytes. Not recommended for anuric patients.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce HCTZ by 25-50% (start at 12.5 mg) due to risk of electrolyte imbalance; reserpine: use lowest effective dose (0.125 mg) and monitor for encephalopathy. Child-Pugh C: avoid HCTZ; reserpine contraindicated due to risk of hepatic coma.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not approved for pediatric use. Limited data: HCTZ 1-2 mg/kg/day orally once or divided; max 50 mg/day. Reserpine 0.01-0.02 mg/kg/day in 1-2 doses; max 0.25 mg/day. Monitor growth, electrolytes, and blood pressure closely in children.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at half the adult dose: HCTZ 12.5 mg orally daily; reserpine 0.05-0.1 mg daily. Titrate slowly (every 2-4 weeks). Monitor for orthostatic hypotension, electrolyte disturbances, depression (reserpine), and dehydration. Avoid in frail elderly due to increased fall risk.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
Reserpine may cause mental depression, especially in patients with a history of depression. Risks are dose-related and may persist after discontinuation. Use with caution or avoid in patients with a history of depression.
None
May cause depression with suicidal risk (reserpine).,May cause electrolyte imbalances (hypokalemia, hyponatremia) due to hydrochlorothiazide.,May increase serum uric acid and precipitate gout.,May cause orthostatic hypotension and bradycardia.,Use cautiously in patients with renal impairment or hepatic disease.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to hydrochlorothiazide, reserpine, or sulfonamide derivatives.,History of depression (especially with reserpine).,Active peptic ulcer or ulcerative colitis (reserpine).,Electroconvulsive therapy (within 1 week).,Severe renal impairment (anuria) or severe hepatic disease.,Pregnancy (especially in second and third trimesters; avoid use).
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-sodium foods to reduce blood pressure; limit alcohol consumption. Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats, fermented foods) as reserpine may potentiate pressor response; however, risk is low with reserpine compared to MAOIs. Maintain potassium-rich diet if hypokalemia risk exists (e.g., bananas, oranges, spinach).
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Reserpine crosses the placenta. First trimester: limited human data but animal studies suggest risk; consider alternative if possible. Second/third trimester: may cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion. Avoid in preeclampsia due to risk of placental hypoperfusion. Risk category C.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Reserpine is excreted into breast milk. M/P ratio approximately 1.6. Potential for infant bradycardia, nasal congestion, and lethargy. Contraindicated in nursing mothers due to risks.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No specific dose adjustments based on pharmacokinetic changes in pregnancy. Use lowest effective dose to minimize fetal risk.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Hydro-Reserp combines hydrochlorothiazide and reserpine; reserpine depletes catecholamines, which may cause depression and sedation. Monitor for orthostatic hypotension and electrolyte imbalances. Avoid in patients with history of depression or peptic ulcer disease. Use with caution in patients with renal impairment.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take this medication exactly as prescribed; do not stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery if affected.,Stand up slowly from sitting or lying down to prevent falls.,Report any signs of depression, unusual mood changes, or slow heartbeat.,Avoid excessive sun exposure; may increase sensitivity to sunlight.,Do not use alcohol while taking this medication.,Monitor blood pressure regularly and keep follow-up appointments.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-RESERP vs ALDORIL D30, answered by our medical review team.
HYDRO-RESERP is a Antihypertensive Combination that works by Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-RESERP and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-RESERP is: HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-RESERP and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-RESERP is classified as Category C. Reserpine crosses the placenta. First trimester: limited human data but animal studies suggest risk; consider alternative if possible. Second/third trimester: may cause neonatal re. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.